SMARCA1 and prostate cancer: In support of this result, it was recently shown by the SILAC-based approach followed by mass spectrometry, that the TMPRSS2-ERG fusion oncoprotein interacts with canonical members of the SWI/SNF complex in a prostate cancer cell line42.